|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.70 TWD | +2.74% |
|
-1.93% | -14.50% |
| Market Cap | 6.1B 189M 164M 153M 140M 265M 18.02B 269M 1.8B 707M 8.97B 709M 693M 30.09B | P/E 2024 |
52.9x | P/E 2025 | 16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 7.21B 223M 194M 181M 166M 313M 21.32B 318M 2.13B 836M 10.61B 839M 820M 35.59B | EV / Sales 2024 |
2x | EV / Sales 2025 | 1.7x |
| Free-Float |
78.86% | Yield 2024 |
4.36% | Yield 2025 | 5.06% |
| 1 day | +2.74% | ||
| 1 week | -1.93% | ||
| Current month | -5.94% | ||
| 1 month | -5.94% | ||
| 3 months | -6.28% | ||
| 6 months | -11.83% | ||
| Current year | -14.50% |
| 1 week | 48.5 |  | 51.9 |
| 1 month | 48.5 | | 56.7 |
| Current year | 48.5 | | 62.5 |
| 1 year | 48.5 | | 72 |
| 3 years | 48.5 | | 121 |
| 5 years | 44.2 | | 121 |
| 10 years | 29.75 | | 121 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
CEO | Chief Executive Officer | - | 01/01/1996 |
Yue Chen Lo
DFI | Director of Finance/CFO | - | 14/04/2003 |
Chin Yuan Lin
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
CHM | Chairman | - | 01/01/1996 |
Che Jen Chuang
BRD | Director/Board Member | - | 18/06/2012 |
Hung Min Hsieh
BRD | Director/Board Member | - | 28/08/2006 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.74% | -1.93% | -24.55% | -48.16% | 183M | |
| -0.53% | -3.95% | +55.23% | +152.74% | 1,030B | |
| +0.21% | -2.68% | +55.61% | +53.02% | 617B | |
| -2.51% | -3.25% | +32.76% | +67.76% | 455B | |
| +0.06% | +1.17% | +36.21% | +31.25% | 350B | |
| -0.14% | -0.83% | +33.24% | +40.28% | 299B | |
| -0.69% | -0.44% | +9.86% | +14.23% | 265B | |
| -7.37% | -4.31% | -5.69% | -41.99% | 225B | |
| -0.64% | +2.43% | +30.52% | +64.49% | 209B | |
| -0.82% | +0.70% | +15.96% | +71.01% | 163B | |
| Average | -0.97% | +1.07% | +23.91% | +40.46% | 361.28B | |
| Weighted average by Cap. | -1.02% | -0.11% | +38.47% | +72.84% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 4.73B 147M 127M 119M 109M 206M 13.99B 209M 1.4B 548M 6.96B 550M 538M 23.35B | 4.85B 150M 131M 122M 112M 211M 14.34B 214M 1.43B 562M 7.14B 564M 552M 23.94B |
| Net income | 157M 4.87M 4.23M 3.94M 3.62M 6.83M 465M 6.94M 46.45M 18.23M 231M 18.29M 17.89M 776M | 441M 13.66M 11.87M 11.05M 10.15M 19.16M 1.3B 19.46M 130M 51.13M 649M 51.3M 50.17M 2.18B |
| Net Debt | 1.2B 37.03M 32.19M 29.97M 27.51M 51.96M 3.54B 52.76M 353M 139M 1.76B 139M 136M 5.9B | 1.12B 34.54M 30.03M 27.95M 25.66M 48.46M 3.3B 49.21M 329M 129M 1.64B 130M 127M 5.5B |
Employees
-
Sector
Pharmaceuticals
Calendar
08-24
Ex-dividend date - 3 TWD
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/07/26 | NT$50.70 | +2.74% | 759,332 |
| 30/07/26 | NT$49.35 | -0.70% | 380,920 |
| 29/07/26 | NT$49.70 | -1.58% | 1,082,816 |
| 28/07/26 | NT$50.50 | -2.13% | 592,519 |
| 27/07/26 | NT$51.60 | +0.78% | 245,763 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4746 Stock
Select your edition
All financial news and data tailored to specific country editions
